Treatment of b-cell malignancies

• Main Authors: LAI, ROBERT, K, MULLER, OLIVIER, AFTAB BAHRAM, GALMI FABRIZIO
• Format: Patent
• Language: Chinese; English
• Published: 20.08.2024
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Aspects of the present disclosure include methods of effectively treating a recurrent/refractory B-cell malignancy in a patient in need thereof that has previously received treatment with at least one, two, or at least three previous therapies and ultimately failed. In one example, a method comprises administering to a subject one or more doses, the one or more doses comprising a therapeutically effective amount of an anti-CD20 CAR [gamma] [delta] T cell that expresses a chimeric antigen receptor (CAR) that comprises a binding domain that specifically binds to CD20 on a malignant B cell of the subject. Upon administration, the subject methods also optionally include one or more biomarkers that monitor cell activation and/or treatment efficacy, the one or more biomarkers informing the need and/or type of subsequent treatment regimen. 本公开的方面包括有效治疗有需要的患者的复发性/难治性B细胞恶性肿瘤的方法，所述患者之前已经接受至少一种、二种或至少三种先前的疗法的治疗并最终失败。在一个实例中，方法包括向受试者施用一个或多个剂量，所述一个或多个剂量包含治疗有效量的抗CD20CARγδT细胞，所述抗CD20CARγδT细胞表达嵌合抗原受体(CAR)，所述嵌合抗原受体包含与受试者的恶性B细胞上